Genetic testing in women with breast cancer: implications for treatment

References

• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.
   PubMed Web of Science ®Google Scholar
• Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792.
   PubMed Web of Science ®Google Scholar
• Nelson H, Fu R, Goddard K, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. preventive services task force recommendation. Evidence synthesis No. 101. AHRQ publication No. 12-05164-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
   Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. [cited 2017 Feb 1]. Available from: http://globocan.iarc.fr
   Google Scholar
• McBrie KA, Ballinger ML, Killick E, et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014;11:260–271.
   PubMed Web of Science ®Google Scholar
• Antoniou A, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:497–506.
   PubMed Web of Science ®Google Scholar
• Michailidou K, Beesley J, Lindstrom S, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47:373–380.
   PubMed Web of Science ®Google Scholar
• Orban TI, Olah E. Emerging roles of BRCA1 alternative splicing. Mol Pathol. 2003;56(4):191–197.
   PubMedGoogle Scholar
• Panier S, Boulton SJ. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol. 2014;15:7–18.
   PubMed Web of Science ®Google Scholar
• Cejka P. DNA end resection: nucleases team up with the right partners to initiate homologous recombination. J Biol Chem. 2015;290(38):22931–22938.
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Chiu JW, Koller BH, et al. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;14:511–518.
   Web of Science ®Google Scholar
• Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. Embo J. 2001;14:4704–4716.
   Web of Science ®Google Scholar
• de Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012;84:137–146.
   PubMed Web of Science ®Google Scholar
• Ali AA, Timinszky G, Arribas-Bosacoma R, et al. The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat Struct Mol Biol. 2012;19:685–692.
   PubMed Web of Science ®Google Scholar
• Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju091.
   PubMedGoogle Scholar
• Vos JR, Hsu L, Brohet RM, et al. Bias correction methods explain much of the variation seen in breast cancer risks of BRCA1/2 mutation carriers. J Clin Oncol. 2015;33(23):2553–2562.
   PubMed Web of Science ®Google Scholar
• Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian breast cancer family study. Cancer Epidemiol Biomarkers Prev. 1999;8(9):741–747.
   PubMed Web of Science ®Google Scholar
• Simchoni S, Friedman E, Kaufman B, et al. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci USA. 2006;103(10):3770–3774.
   PubMed Web of Science ®Google Scholar
• Brohet RM, Velthuizen ME, Hogervorst FB, et al. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet. 2014;51(2):98–107.
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. AmJ Hum Genet. 1998;62(3):676–689.
   PubMed Web of Science ®Google Scholar
• Kuchenbaecker K, Hopper J, Barnes D. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Jama. 2017;317:2402–2416. DOI:10.1001/jama.2017.7112.
   PubMed Web of Science ®Google Scholar
• Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887–5892.
   PubMed Web of Science ®Google Scholar
• Kirova YM, Savignoni A, Sigal-Zafrani B, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2010;120(1):119–126.
   PubMed Web of Science ®Google Scholar
• van den Broek AJ, Van ‘T Veer LJ, Hooning MJ, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. J Clin Oncol. 2016;34(5):409–418.
   PubMed Web of Science ®Google Scholar
• Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28:2404–2410.
   PubMed Web of Science ®Google Scholar
• Tai Y, Domchek S, Parmigiani G, et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99:1811–1814.
   PubMed Web of Science ®Google Scholar
• George S, Garcia R, Slomovitz B. Ovarian cancer: the fallopian tube as the site of origin and opportunities for prevention. Front Oncol. 2016;6:108.
   PubMed Web of Science ®Google Scholar
• Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–1333.
   PubMed Web of Science ®Google Scholar
• Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105:1230–1234.
   PubMed Web of Science ®Google Scholar
• Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106:1697–1701.
   PubMed Web of Science ®Google Scholar
• Taylor RA, Fraser M, Livingstone J, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun. 2017;8:13671.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107:2005–2009.
   PubMed Web of Science ®Google Scholar
• Moran A, O’Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer. 2012;11:235–242.
   PubMed Web of Science ®Google Scholar
• Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269–275.
   PubMed Web of Science ®Google Scholar
• Phelan CM, Iqbal J, Lynch HT, et al. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014;110:530–534.
   PubMed Web of Science ®Google Scholar
• Segev Y, Iqbal J, Lubinski J, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013;130:127–131.
   PubMed Web of Science ®Google Scholar
• Lee Y, Milne R, Lheureux S, et al. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers. Eur J Cancer. 2017;84:114–120.
   PubMed Web of Science ®Google Scholar
• Shu CA, Pike MC, Jotwani AR, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2(11):1434–1440.
   PubMed Web of Science ®Google Scholar
• Milne RL, Antoniou AC. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. Endocr Relat Cancer. 2016;23:T69–84.
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. Jama. 2015;313:1347–1361.
   PubMed Web of Science ®Google Scholar
• Evans DG, Harkness E, Lalloo F, et al. Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. J Med Genet. 2014;51:573–580.
   PubMed Web of Science ®Google Scholar
• Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118:2281–2284.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31:3091–3099.
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Rookus M, Andrieu N, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 carrier cohort study. Cancer Epidemiol Biomarkers Prev. 2009;18:601–610.
   PubMed Web of Science ®Google Scholar
• Gronwald J, Byrski T, Huzarski T, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat. 2006;95:105–109.
   PubMed Web of Science ®Google Scholar
• Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–4198.
   PubMed Web of Science ®Google Scholar
• Lecarpentier J, Nogues C, Mouret-Fourme E, et al. Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). Breast Cancer Res. 2012;14(4):R99.
   PubMed Web of Science ®Google Scholar
• Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta. 2015;1856:73–85.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Jama. 2010;304:967–975.
   PubMed Web of Science ®Google Scholar
• Heemskerk-Gerritsen B, Menke-Pluijmers M, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol. 2013;24(8):2029–2035.
   PubMed Web of Science ®Google Scholar
• Finch A, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547–1553.
   PubMed Web of Science ®Google Scholar
• Heemskerk-Gerritsen BA, Seynaeve C, Van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107:5.
   Google Scholar
• Chai X, Domcheck S, Kauff N, et al. Re: breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(9). DOI:10.1093/jnci/djv217
   PubMedGoogle Scholar
• Kotsopoulos J, Huzarski T, Gronwald J, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2017;109(1):djw177.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology, genetic/familial high-risk assessment: breast and ovarian. [cited 2017 Feb 22]. Available from https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
   Google Scholar
• Stan DL, Shuster LT, Wick MJ, et al. Challenging and complex decisions in the management of the BRCA mutation carrier. J Women’s Health. 2013;22(10):825–834.
   PubMed Web of Science ®Google Scholar
• Litton J, Ready K, Chen H, et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012;118(2):321–325.
   PubMed Web of Science ®Google Scholar
• Rennert G, Bisland-Naggan S, Barnett-Griness O. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357:115–123.
   PubMed Web of Science ®Google Scholar
• Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat. 2010;119(1):13–24.
   PubMed Web of Science ®Google Scholar
• Huzarski T, Byrski T, Gronwald J, et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol. 2013;31:3191–3196.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Mar 3]. Available from: https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf?v=1 page 12.
   Google Scholar
• Zhong Q, Peng H, Zhao X, et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2015;21:211–220.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol. 1999;17:3653–3663.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Vanden Broek AJ, Tollenaar R, et al. Breast cancer survival of BRCA1/BRCA2 mutation carriers in a hospital-based cohort of young women. Jnci. 2017;109. DOI:10.1093/jnci/djw329
   Google Scholar
• Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast cancer family registry population-based cohort study. J Clin Oncol. 2012;30:19–26.
   PubMed Web of Science ®Google Scholar
• Shah P, Patil S, Dickler M, et al. Twenty-one–gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status. Cancer. 2016;122(8):1178–1184.
   PubMed Web of Science ®Google Scholar
• Jonasson J, Stefansson O, Johannsson O, et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer. 2016;115:776–783.
   PubMed Web of Science ®Google Scholar
• Arun B, Bayraktar S, Liu DD, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011;29(28):3739–3746.
   PubMed Web of Science ®Google Scholar
• Heemskerk-Gerritsen B, Rookus M, Aalfs C, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668–677. DOI:10.1002/ijc.29032.
   PubMed Web of Science ®Google Scholar
• Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121(2):389–398.
   PubMed Web of Science ®Google Scholar
• Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009;16(12):3380–3387.
   PubMed Web of Science ®Google Scholar
• Kiely B, Jenkins M, McKinley J, et al. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Res Treat. 2010;120:715–723.
   PubMed Web of Science ®Google Scholar
• Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. Bmj. 2014;348:g226.
   PubMed Web of Science ®Google Scholar
• Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140(1):135–142.
   PubMed Web of Science ®Google Scholar
• Metcalfe K, Lynch HT, Ghadirian P, et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011;127(1):287–296.
   PubMed Web of Science ®Google Scholar
• Shanley S, McReynolds K, Ardern-Jones A, et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res. 2006;12(23):7025–7032.
   PubMed Web of Science ®Google Scholar
• Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104.
   PubMed Web of Science ®Google Scholar
• Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654–2663.
   PubMed Web of Science ®Google Scholar
• Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1 positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375–379.
   PubMed Web of Science ®Google Scholar
• Tutt A, Ellis P, Kilburn L, et al. The TNT trial. 2014 San Antonio breast cancer symposium. Abstract S3-01. [cited 2017 Dec 11]. Available from: http://www.sabcs.org/Portals/SABCS/Documents/2014SABCSCall4Abstracts.pdf
   Google Scholar
• Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014;147:401–405.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT01670500
   Google Scholar
• Hahnen E, Lederer B, Hauke J, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial. JAMA Oncol. 2017 [cited Jul 31]. DOI:10.1001/jamaoncol.2017.1007
   PubMedGoogle Scholar
• [cited 2017 Feb 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02488967
   Google Scholar
• Balmaña J, Tung NM, Isakoff SJ, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014;25(8):1656–1663.
   PubMed Web of Science ®Google Scholar
• Del Conte G, Sessa C, Von Moos R, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer. 2014;111(4):651–659.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134.
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–244.
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244–250.
   PubMed Web of Science ®Google Scholar
• Tesaro, Inc. A phase III trial of niraparib versus physician’s choice in Her2 negative, germline BRCA mutation-positive breast cancer patients (BRAVO). [cited 2017 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01905592
   Google Scholar
• BioMarin Pharmaceutical. A study evaluating talazoparib (BMN 673), a PARP inhibitor, in advanced and/or metastatic breast cancer patients with BRCA mutation (EMBRACA Study). [cited 2017 Jan 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT01945775.
   Google Scholar
• [cited 2017 Jan 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02163694
   Google Scholar
• AstraZeneca. Assessment of the efficacy and safety of olaparib monotherapy versus physicians choice chemotherapy in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. (OlympiAD). [cited 2017 Jan 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02000622.
   Google Scholar
• Robson M, Im S, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–533. DOI:10.1056/NEJMoa17064.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Feb 9]. Available from: https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf?v=1(abstract S2-05 page 14)
   Google Scholar
• European Medicines Agency. [cited 2017 Jan 3]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003726/smops/Positive/human_smop_000744.jsp&mid=WC0b01ac058001d127.
   Google Scholar
• U. S. Food and Drug Administration. [cited 2017 Jan 3]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm
   Google Scholar
• AstraZeneca. Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer (OlympiA). [cited 2017 Jan 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02032823.
   Google Scholar
• Montoni A, Robu M, Pouliot E, et al. Resistance to PARP-inhibitors in cancer therapy. Front Pharmacol. 2013;4:18–25.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–1834.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67–75.
   PubMed Web of Science ®Google Scholar
• King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. Jama. 2001;286(18):2251–2256.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Lindeman GJ. Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen? Future Med. 2014;10:499–502.
   Google Scholar
• Metcalfe K, Lynch HT, Foulkes WD, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 2015;1:306–313.
   PubMed Web of Science ®Google Scholar
• Francis PA, Regan MM, Fleming GF, et al. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med. 2015;372:436–446.
   PubMed Web of Science ®Google Scholar
• Watts K, Meiser B, Mitchell G, et al. How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. Cancer. 2012;12:320–332.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Aug 3]. Available from: https://myriad.com/patients-families/genetic-testing-101/genetic-testing-faqs/accessed 3/8/17
   Google Scholar
• Klee E, Hoppman-Chaney N, Ferber M. Expanding DNA diagnostic panel testing: is more better? Expert Rev Mol Diagn. 2011;11:703–709.
   PubMed Web of Science ®Google Scholar
• Schlich-Bakker K, Wárlám-Rodenhuis C, Van Echtelt J, et al. Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer. 2006;42(16):2722–2728.
   PubMed Web of Science ®Google Scholar
• Meiser B, Gleeson M, Watts K, et al. Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing. Oncol Nurs Forum. 2012;39(2):E101–E111.
   PubMedGoogle Scholar
• Balman J, Dıez O, Rubio I, et al. BRCA in breast cancer: ESMO clinical practice. Annals Oncol. 2011;22(S6):vi31–vi34. DOI:10.1093/annonc/mdr373.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Mar 3]. Available from: https://www.nice.org.uk/guidance/cg164/chapter/1-recommendations#genetic-testing
   Google Scholar
• [cited 2017 Feb 22]. Available from: https://www.eviq.org.au/Protocol/tabid/66/categoryid/439/id/1620/Referral+Guidelines+for+Breast+Cancer+Risk+Assessment+and+Consideration+of+Genetic+Testing.aspx.
   Google Scholar
• Lee A, Cunningham A, Kuchenbaecker K, et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2014;110:535–545.
   PubMed Web of Science ®Google Scholar
• Kast K, Schmutzler R, Rhiem K, et al. Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. Int J Cancer. 2014;135(10):2352–2361.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Mar 3]. Available from: http://www.ascopost.com/issues/february-10-2015/dr-mary-claire-king-proposes-population-screening-in-all-young-women-for-brca-mutations/
   Google Scholar
• Kurian AW, Griffith KA, Hamilton AS, et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. Jama. 2017;317(5):531–534.
   PubMed Web of Science ®Google Scholar
• Plon SE, Eccles DM, Easton D, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282–1291.
   PubMed Web of Science ®Google Scholar
• I Eggington JM, Bowles KR, Moyes K, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet. 2014;86:229–237.
   PubMed Web of Science ®Google Scholar
• Eccles D, Mitchell G, Monteiro A, et al. BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significance. Annals Oncol. 2015;26:2057–2065.
   PubMed Web of Science ®Google Scholar
• Murray M, Cerrato F, Bennett R, et al. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med. 2011;13:998–1005.
   PubMed Web of Science ®Google Scholar
• Karakasis K, Burnier J, Bowering V, et al. Ovarian cancer and BRCA1/2 testing: opportunities to improve clinical care and disease prevention. Front Oncol. 2016;6:119.
   PubMed Web of Science ®Google Scholar